MARKET

SPRO

SPRO

Spero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.90
0.00
0.00%
After Hours: 15.90 0 0.00% 16:19 11/24 EST
OPEN
16.00
PREV CLOSE
15.90
HIGH
16.10
LOW
15.21
VOLUME
272.32K
TURNOVER
--
52 WEEK HIGH
16.94
52 WEEK LOW
5.25
MARKET CAP
432.43M
P/E (TTM)
-3.7754
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Spero Therapeutics EPS beats by $0.03, beats on revenue
Spero Therapeutics (SPRO): Q3 GAAP EPS of -$0.86 beats by $0.03.Revenue of $4M (-13.8% Y/Y) beats by $0.99M.Press Release
Seekingalpha · 11/05 21:37
Spero Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Spero Therapeutics, Inc.
ACCESSWIRE · 11/05 19:30
Spero Therapeutics Reports Will Present Data For All Pipeline Programs At IDWeek 2020 Oct. 21-25
Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug
Benzinga · 10/16 12:35
Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020
15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trialCAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will have 15 data presentations at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 taking place virtually from October 21 - 25, 2020. Presentations will cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial that evaluated Spero’s oral antibiotic investigational candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line data from the trial demonstrating that oral tebipenem HBr was statistically non-inferior to intravenous (IV) ertapenem in the treatment of patients with cUTI and patients with AP. Poster presentations include a poster on the Phase 1 clinical trial of SPR720, an oral antimicrobial investigational agent in clinical development by Spero for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. In December 2019, Spero announced positive data from this Phase 1 double-blind, placebo-controlled single ascending dose and multiple ascending dose clinical trial in healthy volunteers. Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI: Title: Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study Presenting Author: Paul Eckburg Date: Saturday, October 24, 2020 Time: 10:00 – 11:15 AM EDTTitle: Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model Presenting Author: Brian D. VanScoy Date: Wednesday, October 21, 2020 Poster Session: PK/PD Studies Poster Number: 1304Title: Tebipenem: An Oral Carbapenem with Activity Against Multi-drug Resistant Urinary Tract Infection Isolates of Escherichia coli Collected from US Medical Centers During 2019 Presenting Author: Ian A. Critchley Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1695Title: Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US) Presenting Author: Thomas Lodise Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1673Title: Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals Presenting Author: Thomas Lodise Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1683Title: Hospital Costs and Reimbursement in Patients with Resistant Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis Presenting Author: Katherine Sulham Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1684Title: Eligibility and Outcomes of Conversion to Oral (PO) Therapy in Patients Hospitalized with Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis Presenting Author: Katherine Sulham Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1672Title: Pre- and Post-Hospitalization Resource Utilization and Costs Associated with Urinary Tract Infection (UTI) in both Commercial and Medicare Populations Presenting Author: Katherine Sulham Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1691Title: Health Resource Utilization in Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis Presenting Author: Katherine Sulham Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1682Title: Clinical Characteristics and Demographics of Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis Presenting Author: Katherine Sulham Date: Wednesday, October 21, 2020 Poster Session: UTIs Poster Number: 1670Presentations pertaining to SPR720, Spero’s novel investigational oral antibacterial agent that targets enzymes essential for bacterial DNA replication:Title: Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections Presenting Author: Angela Talley Date: Wednesday, October 21, 2020 Poster Session: Novel Agents Poster Number: 1288Title: SPR720, A Novel Benzimidazole Gyrase Inhibitor, Demonstrates Potent Efficacy Against Mycobacterium avium ATCC 700898 in a Chronic C3HeBFeJ Mouse Infection Model Presenting Author: Nicole S. Cotroneo Date: Wednesday, October 21, 2020 Poster Session: Tuberculosis and other Mycobacterial Infections Poster Number: 1637Title: Evaluating the Activity of SPR719, a Novel Aminobenzimidazole, against Nontuberculous Mycobacteria Presenting Author: Chris Pillar Date: Wednesday, October 21, 2020 Poster Session: Novel Agents Poster Number: 1274Title: Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease Presenting Author: Tawanda Gumbo Date: Wednesday, October 21, 2020 Poster Session: Tuberculosis and other Mycobacterial Infections Poster Number: 1659Presentations pertaining to SPR206, Spero’s next generation polymyxin investigational product candidate being developed to treat multi-drug resistant (MDR) Gram-negative infections in the hospital setting: Title: Activity of SPR206, a Polymyxin B derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains Presenting Author: Jacinda C. Abdul-Mutakabbir Date: Wednesday, October 21, 2020 Poster Session: PK/PD studies Poster Number: 1295Abstracts are accessible via the IDWeek™ website. Poster presentations may be accessed through Spero Therapeutics’ website on the “Key Publications and Presentations” page under the “Pipeline” tab following their completion.About Tebipenem HBr Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) is Spero’s novel investigational oral formulation of tebipenem pivoxil, a carbapenem antibiotic of the β-lactam class marketed by Meiji Seika Pharma Co. Ltd. (Meiji) in Japan as Orapenem® since 2009 for pediatric infections limited to pneumonia, otitis media and sinusitis. Orapenem® is not approved in the U.S. Carbapenems are an important subclass of antibiotics because they have been observed to be safe and effective in the treatment of drug-resistant Gram-negative bacterial infections. Tebipenem HBr is being developed for the treatment of cUTI, including AP. Spero expects to submit a New Drug Application submission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr in the second quarter of 2021. If approved, tebipenem HBr would be the first oral carbapenem to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP.About SPR720 SPR720 represents a novel class of antibacterial agents in development that target enzymes essential for bacterial DNA replication. SPR720, an investigational new drug, was acquired from Vertex Pharmaceuticals and is currently under clinical development by Spero as an oral therapy for the treatment of non-tuberculous mycobacterial (NTM) pulmonary disease, a rare chronic orphan disease. Spero plans to initiate enrollment in its planned Phase 2a clinical trial evaluating SPR720 in patients with NTM pulmonary disease by year-end 2020.Non-tuberculous mycobacteria are ubiquitous environmental pathogens that can cause progressive lung damage and respiratory failure, particularly in patients with compromised immune systems or underlying pulmonary disorders. Although rare, the incidence of NTM pulmonary disease is increasing worldwide. Treatment of NTM pulmonary disease requires prolonged therapy (continuing for approximately 12 to 24 months) with a combination of drugs approved for other infections and is frequently complicated by tolerability and/or toxicity issues. There are currently no oral antibiotics specifically approved for use to treat NTM pulmonary disease. Thus, if successfully developed and approved by the FDA, SPR720 has the potential to address an important unmet need as the first oral antibiotic approved for the treatment of this debilitating disease. Under Spero’s collaboration with the Bill and Melinda Gates Medical Research Institute, SPR720 will also be developed for the treatment of Mycobacterium tuberculosis (M. tb) infections in select economically disadvantaged countries. M. tb is a priority pathogen as defined by the World Health Organization with tuberculosis being one of the top ten causes of death worldwide and associated with both increasing resistance and sub-optimal current treatment approaches. SPR720 has been granted QIDP designation by the FDA for the treatment of lung infections caused by NTM and lung infections caused by M. tb and Orphan Drug Designation by the FDA for the treatment of NTM infection.About SPR206  SPR206 is an investigational agent designed to be IV administered and act directly on Gram-negative bacterial infections through the molecule’s interactions with the bacterial outer membrane. SPR206 has demonstrated potent broad-spectrum activity against Gram-negative bacteria, including organisms identified by the Centers for Disease Control and Prevention and the World Health Organization as urgent and serious threats to human health. Spero expects to initiate a Phase 1 bronchoalveolar lavage clinical trial assessing the penetration of SPR206 into the pulmonary compartment in the first half of 2021 and initiate a renal impairment study of SPR206 in 2021. SPR206 has been granted QIDP designation by the FDA for the treatment of cUTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).Tebipenem HBr Research Support This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800015C. SPR720 Research Support Research reported in this publication was partially supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number R44AI131749. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.SPR206 Research Support Clinical research for the SPR206 program is funded by The U.S. Army Medical Research Acquisition Activity, 839 Chandler Street, Fort Detrick MD217025014, which is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. W81XWH-19-1-0295. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.Non-clinical research for the SPR206 program is funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201500014C.Non-clinical research for the SPR206 program was funded in part by The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014, which is the awarding and administering acquisition office. This work was supported in part by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-2-0019. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.About Spero Therapeutics Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.For more information, visit https://sperotherapeutics.com.Forward-Looking Statements This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the initiation, timing and submission to the FDA of a NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift from IV to oral administration; the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, including the commencement of Spero’s planned Phase 2a clinical trial of SPR720 and the commencement of Spero’s planned Phase 1 bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and its renal impairment study of SPR206; and management’s assessment of the results of such preclinical studies and clinical trials. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Spero’s ability to timely complete related Phase 1 trials for its planned NDA submission for tebipenem HBr, taking into account the possible effects of the COVID-19 pandemic; Spero’s need for additional funding; the lengthy, expensive, and uncertain process of clinical drug development; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to develop and commercialize Spero’s product candidates, if approved; the potential impact of the COVID-19 pandemic; Spero’s ability to retain key personnel and to manage its growth; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.Spero Investor and Media Contact: Sharon Klahre Senior Director, Investor Relations 857-242-1547 IR@sperotherapeutics.com
GlobeNewswire · 10/16 12:30
Spero Therapeutics (SPRO) Catches Eye: Stock Jumps 7%
Spero Therapeutics (SPRO) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Zacks · 09/30 14:02
Spero Therapeutics initiated at outperform with $70 price target at Evercore ISI
SPRO | Complete Spero Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 09/29 14:34
ITCI, AMRS among premarket losers
Evofem Biosciences (EVFM) -14%.Amyris (AMRS) -11% after Lavvan files $881M lawsuit.Muscle Maker (GRIL) -11%.Brigham Minerals (MNRL) -10% after pricing secondary offering.Satsuma Pharmaceuticals (STSA) -7% on yesterday's news of late-stage STS101 study and analysts downgrade.Spero Therapeutics (SPRO) -8% after pricing equity
Seekingalpha · 09/11 12:21
Spero Therapeutics Announces Pricing of Securities Offering
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bacterial infections and
GlobeNewswire · 09/11 11:54
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPRO. Analyze the recent business situations of Spero through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SPRO stock price target is 28.29 with a high estimate of 70.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 107
Institutional Holdings: 16.76M
% Owned: 61.63%
Shares Outstanding: 27.20M
TypeInstitutionsShares
Increased
30
5.10M
New
27
312.86K
Decreased
21
415.69K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chairman/Independent Director
Milind Deshpande
President/Chief Executive Officer/Director/Primary Contact
Ankit Mahadevia
Chief Financial Officer/Treasurer
.. ..
Chief Financial Officer/Treasurer
Stephen DiPalma
Chief Financial Officer/Treasurer
.. DiPalma
Chief Operating Officer
Cristina Larkin
Chief Scientific Officer
Thomas Parr
Other
Timothy Keutzer
Other
David Melnick
Independent Director
Jean-Francois Formela
Independent Director
Jean-François Formela
Independent Director
Scott Jackson
Independent Director
John Pottage
Independent Director
Cynthia Smith
Independent Director
Frank Thomas
Independent Director
Patrick Vink
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Spero Therapeutics Inc stock information, including NASDAQ:SPRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPRO stock methods without spending real money on the virtual paper trading platform.